@entity4091 and XXXX in Sweden.

@entity1 @entity9 @entity4091
BACKGROUND: The societal economic @entity4091 in Sweden is not well described today. This study is a top-down analysis of Swedish registers with the objective to describe the @entity4091 and @entity9 in Sweden during 2011. METHODS: Data for inpatient care; outpatient primary and specialized cares; the prescriptions of drugs, sick leave and the number or diagnostic tests were collected from Swedish national databases. The incidence of the disease was estimated based on the number of prescriptions of antiviral drugs. RESULTS: The incidence of herpes zoster was estimated to 315 and 577 cases per 100,000 @entity1 for @entity1 at all ages and   >   = 50 years, respectively. Almost 30,000 @entity1 at all ages were diagnosed with herpes zoster and the societal cost to treat these @entity1 , including the cost to treat those @entity1 who later developed @entity9 , added up to nearly 227 MSEK (31.6 M   ) which corresponds to 7,600 SEK (   870) per @entity1 . The main contributors to the total cost for the treatment of HZ @entity1 were primary care (43 %); sick leave (28 %); hospitalization (10 %) and specialist care (7 %). Medication was a relatively small contributor with 8.5 MSEK (4 %; 1.0 M   ) to the overall costs for @entity1 at all ages. The corresponding total cost including only @entity1 50 years and older was 168 MSEK (19.2 M   ) or 8,200 SEK (   939) per @entity1 . CONCLUSIONS: The current study demonstrates that the @entity4091 is significant in Sweden. The society, the health care payers and the @entity1 potentially have a lot to gain by introducing a vaccination program to @entity1 50 years and older and as a consequence reduce the economic and clinical @entity4091 and @entity9 .
